# Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct03775512` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03775512](<https://clinicaltrials.gov/study/NCT03775512>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03775512

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 283 participants.

## Technical summary

Registry record NCT03775512. Non-randomized; no masking; primary purpose treatment. Start 2019-01-30 (actual); primary completion 2022-02-17 (actual). Results posted on 2023-03-16.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 283 participants (enrolled count; ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Started: 2019-01-30 (actual) (ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Primary completion: 2022-02-17 (actual) (ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Completion: 2022-02-17 (actual) (ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Results first posted: 2023-03-16 (ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03775512, source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03775512-2023-03-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation
- Acronym: Q-FFICIENCY
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): RF Ablation with QDOT Micro
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: 3737184662e213058fe06f679e628f9ac45dd58946d71f0db9e3e80311d399cb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
